Treatment of Acute Myeloid Leukaemia with Cytosine Arabinoside and Daunomycin in Combination

19 patients with acute myeloid leukaemia were treated with cytosine arabinoside and daunomycin in combination. The treatment was administered continuously instead of in short cycles. 10 complete and 5 partial remissions were induced. 1 patient was a definite therapeutic failure, while 3 patients did not have adequate trial. Disregarding the latter 3 patients the overall remission frequency was 94 %. 8 of 11 patients more than 60 years old acquired remissions, of which 4 were complete. The median survival was 8 months for the entire series, and the mean duration of the remissions was 5 months.